Robotic vs. laparoscopic rectal cancer surgery in high BMI patients: a systematic review and meta-analysis.

Clin Transl OncolMay 18, 2026 (epub)
Clinical ResearchGeneral SurgeryOncology (Medical)Open access

Chengzheng Wang, Huaicheng Zhou

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis compared perioperative outcomes of robotic-assisted versus laparoscopic rectal cancer surgeries in patients with high BMI (≥ 28 kg/m²). Analyzing data from five studies involving 700 robotic and 2102 laparoscopic cases, the results indicated that robotic surgery had a significantly lower conversion rate and shorter hospital stay, while laparoscopic surgery had a shorter operative time.

Key findings

  • Robotic surgery had a significantly lower conversion rate compared to laparoscopic surgery (P < 0.05).
  • Laparoscopic surgery was approximately 30 minutes faster than robotic surgery (P < 0.05).
  • Robotic surgery resulted in a significantly shorter length of hospital stay than laparoscopic surgery (P < 0.05).
  • No significant differences were found in harvested lymph nodes or postoperative complications.

Why it matters

Understanding the comparative outcomes of robotic versus laparoscopic surgery in high BMI patients can guide surgical decision-making and optimize patient care, particularly in a population that may face increased surgical risks.

Source

PubMed · PMID 42151665Free full text on PubMed Central

Published in Clin Transl Oncol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in General Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.